Pharmacology of Uterine Relaxants (Tocolytics)

Introduction/Overview

Uterine relaxants, commonly termed tocolytics, constitute a pharmacologically diverse group of agents employed to inhibit uterine contractions. The primary clinical objective of tocolytic therapy is the prevention or delay of preterm birth, a leading global cause of neonatal morbidity and mortality. By transiently suppressing myometrial activity, these drugs facilitate critical interventions such as the administration of antenatal corticosteroids for fetal lung maturation and the transfer of the mother to a facility with appropriate neonatal intensive care capabilities. The pharmacology of these agents is complex, involving direct and indirect modulation of the intricate cellular signaling pathways that govern myometrial contractility. A thorough understanding of their mechanisms, pharmacokinetic profiles, therapeutic applications, and associated risks is essential for safe and effective clinical use.

Learning Objectives

• Classify the major drug categories used as uterine relaxants based on their primary mechanism of action.
• Explain the molecular and cellular pharmacodynamics through which different tocolytic classes inhibit myometrial contractions.
• Compare and contrast the pharmacokinetic properties, therapeutic regimens, and major adverse effect profiles of the principal tocolytic agents.
• Evaluate the clinical indications for tocolysis, including appropriate patient selection and treatment duration.
• Identify significant drug interactions, contraindications, and special population considerations relevant to tocolytic therapy.

Classification

Tocolytic agents are classified primarily according to their mechanism of action, which targets specific biochemical pathways involved in uterine smooth muscle contraction. This functional classification encompasses several distinct drug classes.

Beta₂-Adrenergic Receptor Agonists

This class includes drugs such as ritodrine and terbutaline. Although ritodrine was previously the only agent approved by the U.S. Food and Drug Administration (FDA) for tocolysis, its approval has been withdrawn; however, both drugs continue to be used in various jurisdictions. They are synthetic sympathomimetic amines with selective affinity for beta₂-adrenergic receptors.

Calcium Channel Blockers

Dihydropyridine calcium channel blockers, most notably nifedipine, are widely used as tocolytics. Their primary action is the blockade of L-type voltage-gated calcium channels. Nifedipine is often considered a first-line agent in many clinical protocols due to its efficacy and tolerability profile.

Cyclooxygenase (COX) Inhibitors

Nonsteroidal anti-inflammatory drugs (NSAIDs) like indomethacin and ketorolac inhibit the cyclooxygenase enzymes, thereby reducing the synthesis of prostaglandins, which are potent stimulators of uterine contractions.

Oxytocin Receptor Antagonists

Atosiban is a competitive antagonist of the oxytocin and vasopressin V_1a receptors. It is a peptide analogue of oxytocin and is available in many countries, though not in the United States, for the treatment of preterm labor.

Magnesium Sulfate

Magnesium sulfate, while not a specific tocolytic, is frequently used for its uterine relaxant effects, particularly in settings of preterm labor or for neuroprotection of the fetus. Its mechanism is non-specific and involves competition with calcium.

Nitric Oxide Donors

Nitroglycerin and other nitric oxide donors act as uterine relaxants by increasing intracellular cyclic guanosine monophosphate (cGMP) levels. Their use is typically reserved for acute situations, such as uterine relaxation during obstetric procedures.

Mechanism of Action

The inhibition of uterine contractions by tocolytics is achieved through interference with the fundamental biochemical processes that generate myometrial force. Uterine smooth muscle contraction is ultimately dependent on an increase in intracellular calcium concentration ([Ca²⁺]_i), which promotes the formation of actin-myosin cross-bridges.

Beta₂-Adrenergic Receptor Agonists

Activation of myometrial beta₂-adrenergic receptors stimulates the membrane-bound enzyme adenylyl cyclase via a G_s protein. This increases intracellular concentrations of cyclic adenosine monophosphate (cAMP). Elevated cAMP activates protein kinase A (PKA), which subsequently phosphorylates key target proteins. Phosphorylation of myosin light-chain kinase (MLCK) inhibits its activity, reducing the phosphorylation of the regulatory myosin light chains necessary for contraction. Furthermore, PKA may enhance calcium sequestration into the sarcoplasmic reticulum and promote the opening of potassium channels, leading to membrane hyperpolarization and reduced calcium influx through voltage-gated channels. The net effect is a decrease in [Ca²⁺]_i and a reduction in myometrial tone and contractility.

Calcium Channel Blockers

Dihydropyridines like nifedipine bind selectively to the alpha-1 subunit of L-type voltage-dependent calcium channels on the myometrial cell membrane, stabilizing them in an inactivated state. This blockade prevents the influx of extracellular calcium ions that typically occurs during depolarization. The reduction in calcium influx lowers [Ca²⁺]_i, thereby decreasing the activation of calmodulin and MLCK. The inhibition of this calcium-calmodulin-MLCK pathway results in diminished myosin light chain phosphorylation and reduced contractile force.

Cyclooxygenase Inhibitors

Prostaglandins, particularly PGE₂ and PGF_2α, are critical mediators of labor initiation and progression. They increase myometrial contractility by sensitizing the myometrium to oxytocin, promoting gap junction formation, and directly stimulating calcium release. NSAIDs such as indomethacin inhibit the cyclooxygenase enzymes (COX-1 and COX-2), which catalyze the conversion of arachidonic acid to prostaglandin G₂ and subsequently to other prostaglandins and thromboxanes. By suppressing prostaglandin synthesis, these agents reduce one of the primary hormonal drivers of uterine contractions.

Oxytocin Receptor Antagonists

Atosiban is a synthetic peptide analogue that competitively antagonizes the binding of endogenous oxytocin to its G protein-coupled receptor on the myometrium. Oxytocin receptor activation normally triggers the phospholipase C (PLC) pathway, leading to the generation of inositol trisphosphate (IP₃) and diacylglycerol (DAG). IP₃ stimulates the release of calcium from intracellular stores in the sarcoplasmic reticulum. By blocking this receptor, atosiban prevents the oxytocin-induced rise in [Ca²⁺]_i. It also exhibits antagonistic activity at the vasopressin V_1a receptor, which shares structural homology with the oxytocin receptor and can also promote uterine contractions.

Magnesium Sulfate

The tocolytic mechanism of magnesium sulfate is multifactorial and not fully specific. Magnesium ions (Mg²⁺) act as a physiological calcium antagonist. They compete with calcium for entry into cells through voltage-gated channels and may also reduce the release of calcium from sarcoplasmic stores. At the intracellular level, Mg²⁺ competes with Ca²⁺ for binding sites on proteins, including calmodulin, thereby impairing the activation of MLCK. Additionally, magnesium may enhance the uptake of calcium into the sarcoplasmic reticulum and promote membrane stabilization through effects on sodium-potassium ATPase activity.

Nitric Oxide Donors

Nitric oxide (NO) donors, such as nitroglycerin, release NO, which diffuses into myometrial cells. NO activates soluble guanylyl cyclase (sGC), increasing the synthesis of cyclic guanosine monophosphate (cGMP). Elevated cGMP activates protein kinase G (PKG), which leads to a decrease in [Ca²⁺]_i through mechanisms that include stimulation of calcium extrusion and sequestration. PKG may also phosphorylate and inhibit MLCK and activate myosin light chain phosphatase, promoting relaxation. The net effect is a rapid reduction in uterine tone.

Pharmacokinetics

The pharmacokinetic properties of tocolytics significantly influence their dosing regimens, route of administration, and monitoring requirements.

Beta₂-Adrenergic Receptor Agonists

Ritodrine and terbutaline are typically administered intravenously for acute tocolysis, with oral maintenance therapy sometimes employed. Following intravenous infusion, ritodrine has an onset of action within 5-10 minutes. It undergoes extensive first-pass metabolism when given orally, leading to low and variable bioavailability (approximately 30%). The drug is metabolized in the liver via conjugation to sulfate and glucuronide derivatives. The elimination half-life is relatively short, ranging from 1.5 to 3 hours, necessitating continuous infusion for sustained effect. Terbutaline exhibits similar pharmacokinetics, with a half-life of 3-4 hours and bioavailability of about 15% after oral administration due to significant first-pass metabolism.

Calcium Channel Blockers

Nifedipine is almost exclusively administered orally for tocolysis, often using immediate-release capsules. Its absorption from the gastrointestinal tract is rapid and nearly complete (>90%), but bioavailability is reduced to approximately 45-55% due to first-pass hepatic metabolism. Peak plasma concentrations (C_max) are achieved within 30 to 60 minutes. Nifedipine is highly protein-bound (>95%) and is metabolized extensively in the liver by the cytochrome P450 3A4 (CYP3A4) enzyme system to inactive metabolites. The elimination half-life is 2-5 hours, but its pharmacodynamic effect on the uterus may outlast its plasma concentration, allowing for dosing intervals of 4-8 hours. Sublingual or buccal administration is not recommended due to the risk of precipitous hypotension.

Cyclooxygenase Inhibitors

Indomethacin is well absorbed orally, with bioavailability exceeding 90%. It reaches peak plasma concentrations in about 2 hours. The drug is highly bound to plasma proteins (>99%). Metabolism occurs primarily in the liver via O-demethylation, N-deacylation, and conjugation. Indomethacin undergoes enterohepatic recirculation. Its elimination half-life varies but is typically 4-6 hours. Renal excretion of unchanged drug and metabolites is the primary route of elimination. Due to concerns regarding fetal adverse effects, the duration of therapy is usually limited to 48-72 hours.

Oxytocin Receptor Antagonists

Atosiban is administered as an intravenous regimen due to its peptide nature, which precludes oral bioavailability. It is given as an initial bolus injection, followed by a continuous infusion. The drug exhibits linear pharmacokinetics. Atosiban is metabolized via peptide bond hydrolysis, and its metabolites are presumed inactive. The terminal elimination half-life is approximately 18 minutes, with a total body clearance of around 41 L/h. Steady-state concentrations are achieved rapidly during infusion, and the drug is cleared from plasma within an hour after infusion cessation.

Magnesium Sulfate

Magnesium sulfate is administered intravenously for tocolysis. Intramuscular injection is also possible but less common due to pain. After intravenous infusion, magnesium distributes widely, with a volume of distribution approximating the extracellular fluid compartment. It is not metabolized and is eliminated almost entirely by the kidneys via glomerular filtration. Renal clearance is directly proportional to creatinine clearance. The half-life is variable but is approximately 4-6 hours in patients with normal renal function. Serum magnesium levels must be monitored closely to maintain therapeutic levels (typically 4-8 mg/dL or 1.6-3.3 mmol/L) and avoid toxicity.

Nitric Oxide Donors

Nitroglycerin used for uterine relaxation is typically given via transdermal patch or intravenous infusion. It undergoes extensive first-pass metabolism when given orally, making non-parenteral routes necessary. Nitroglycerin is rapidly metabolized by hepatic and vascular mitochondrial aldehyde dehydrogenase to dinitrates and mononitrates, which possess minimal vasodilatory activity. The parent compound has an extremely short half-life of 1-4 minutes. Its effects are rapid in onset and short-lived after discontinuation of the infusion.

Therapeutic Uses/Clinical Applications

The principal application of tocolytic drugs is the management of acute preterm labor, defined as regular uterine contractions with documented cervical change occurring between 20 and 37 weeks of gestation. The goal is typically to achieve a 48-hour delay in delivery to allow for corticosteroid administration and maternal transfer.

Approved Indications

Formal regulatory approvals for tocolysis vary by country. Atosiban is licensed specifically for the inhibition of uncomplicated preterm labor in many countries outside the United States. Nifedipine, while widely used and endorsed by professional guidelines, is employed off-label for tocolysis in most regions, as its primary approval is for hypertension and angina. Similarly, indomethacin and terbutaline are used off-label for this purpose. Magnesium sulfate is approved for the prevention and treatment of seizures in preeclampsia/eclampsia, with its tocolytic use being an accepted, though not formally labeled, application.

Clinical Protocols and Agent Selection

Agent selection is guided by gestational age, maternal contraindications, fetal status, and institutional protocols. Nifedipine is often a first-line oral agent due to its favorable efficacy and side effect profile relative to beta-agonists. Indomethacin is frequently considered a first-line agent before 32 weeks of gestation but is typically avoided thereafter due to concerns about fetal ductus arteriosus constriction and oligohydramnios. Atosiban is used as an alternative, particularly when maternal cardiovascular contraindications exist for other agents. Beta-agonists are less commonly used as first-line therapy in contemporary practice due to their significant maternal side effects. Magnesium sulfate is often used as a second-line agent or in specific clinical scenarios.

Other Obstetric Applications

Uterine relaxants have roles beyond acute preterm labor. They may be used for external cephalic version to facilitate manipulation of the fetus. Tocolytic agents are also employed to achieve uterine quiescence during certain fetal surgical procedures or to manage uterine hyperstimulation caused by oxytocin during labor induction. Nitroglycerin is particularly useful for acute intraoperative uterine relaxation, such as during the removal of a retained placenta or the delivery of a second twin in a non-vertex presentation.

Adverse Effects

The use of tocolytic agents is associated with a spectrum of adverse effects, ranging from common and bothersome side effects to rare but serious complications. The risk profile varies considerably between drug classes.

Beta₂-Adrenergic Receptor Agonists

These agents are notorious for their systemic side effects due to stimulation of extra-uterine beta₂ receptors and, at higher doses, beta₁ receptors.

• Common Maternal Effects: Tachycardia, palpitations, tremor, anxiety, headache, nausea, and flushing. Hyperglycemia and hypokalemia are frequent metabolic consequences due to insulin secretion and intracellular potassium shift, respectively.
• Serious Maternal Effects: Pulmonary edema is a potentially life-threatening complication, risk factors for which include multiple gestation, concurrent corticosteroid use, and fluid overload. Cardiac arrhythmias, myocardial ischemia, and hypotension may also occur.
• Fetal/Neonatal Effects: Fetal tachycardia is common. Neonatal hypoglycemia, ileus, and hypocalcemia have been reported following prolonged maternal treatment.

Calcium Channel Blockers

Nifedipine is generally better tolerated than beta-agonists, but side effects related to systemic vasodilation are common.

• Common Maternal Effects: Headache, flushing, dizziness, peripheral edema, and nausea. Reflex tachycardia may occur secondary to hypotension.
• Serious Maternal Effects: Significant hypotension is a risk, particularly with rapid administration or in volume-depleted patients. Pulmonary edema is rare but possible. Concurrent use with magnesium sulfate may potentiate neuromuscular blockade.
• Fetal Effects: Generally considered minimal, though fetal heart rate abnormalities secondary to maternal hypotension are possible.

Cyclooxygenase Inhibitors

Adverse effects stem from the inhibition of prostaglandin synthesis in various tissues.

• Common Maternal Effects: Gastrointestinal disturbances (nausea, dyspepsia, gastritis), and headache.
• Serious Maternal Effects: Renal impairment, particularly in women with pre-existing kidney disease or volume depletion. Platelet dysfunction may increase bleeding risk.
• Fetal/Neonatal Effects: The primary concerns are fetal. Constriction of the ductus arteriosus, which can lead to pulmonary hypertension, is a significant risk, especially after 32 weeks of gestation or with prolonged use. Oligohydramnios due to reduced fetal renal blood flow is another well-documented complication. Neonatal necrotizing enterocolitis, intracranial hemorrhage, and hyperbilirubinemia have been associated with antenatal indomethacin exposure.

Oxytocin Receptor Antagonists

Atosiban is noted for its favorable maternal cardiovascular safety profile.

• Common Maternal Effects: Nausea, vomiting, headache, and injection site reactions are the most frequently reported. Tachycardia and hypotension are uncommon.
• Serious Maternal Effects: Serious adverse events are rare. Hypersensitivity reactions are a theoretical concern.
• Fetal/Neonatal Effects: No specific pattern of serious fetal adverse effects has been consistently demonstrated, contributing to its safety profile.

Magnesium Sulfate

Adverse effects are dose-dependent and correlate with serum magnesium levels.

• Common Maternal Effects: Flushing, sweating, a sensation of warmth, nausea, and lethargy are common at therapeutic levels.
• Signs of Toxicity: Loss of deep tendon reflexes occurs at levels >10 mg/dL. Respiratory depression occurs at levels >12-15 mg/dL, and cardiac arrest can occur at levels >25 mg/dL.
• Fetal/Neonatal Effects: Neonatal hypotonia, respiratory depression, and hypocalcemia can occur if high maternal levels are present at delivery.

Nitric Oxide Donors

• Common Maternal Effects: Headache (often severe), hypotension, tachycardia, and dizziness.
• Serious Maternal Effects: Methemoglobinemia is a rare but serious complication with high doses. Rebound uterine hypertonus may occur after discontinuation.

Drug Interactions

Concurrent use of tocolytics with other medications requires careful consideration due to the potential for additive pharmacodynamic effects or pharmacokinetic alterations.

Major Drug-Drug Interactions

• Beta-agonists with Corticosteroids: Concurrent administration of betamethasone or dexamethasone for fetal lung maturation significantly increases the risk of maternal pulmonary edema and hyperglycemia.
• Beta-agonists with Other Sympathomimetics or Theophylline: Additive cardiovascular stimulation (tachycardia, arrhythmias) and hypokalemia may occur.
• Nifedipine with CYP3A4 Inhibitors: Drugs such as ketoconazole, itraconazole, erythromycin, and clarithromycin can inhibit nifedipine metabolism, leading to elevated plasma levels and increased risk of hypotension and other adverse effects.
• Nifedipine with Magnesium Sulfate: Concomitant use may theoretically potentiate neuromuscular blockade and hypotension, though this combination is often used clinically with close monitoring.
• Indomethacin with Antihypertensives: NSAIDs can attenuate the effects of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and diuretics by inhibiting renal prostaglandin synthesis, potentially reducing their antihypertensive efficacy.
• Indomethacin with Anticoagulants/Antiplatelets: Increased risk of bleeding due to additive effects on platelet function.
• Magnesium Sulfate with Neuromuscular Blocking Agents: Potentiation of neuromuscular blockade can occur, which is relevant if general anesthesia is required.
• Magnesium Sulfate with Calcium Channel Blockers: As noted, additive hypotension and cardiac depression are possible.

Contraindications

Contraindications are often class-specific and must be strictly observed.

• General Contraindications to Tocolysis: These include chorioamnionitis, severe preeclampsia/eclampsia, placental abruption, non-reassuring fetal status, significant vaginal bleeding of unknown etiology, intrauterine fetal demise, and lethal fetal anomaly.
• Beta-agonists: Contraindicated in patients with cardiac arrhythmias, poorly controlled diabetes mellitus, hyperthyroidism, and severe hypertension.
• Calcium Channel Blockers: Relative contraindications include maternal hypotension, cardiac disease with reduced ventricular function, and concomitant use of strong CYP3A4 inhibitors.
• COX Inhibitors: Contraindicated in patients with aspirin/NSAID-induced asthma, active peptic ulcer disease, renal impairment, platelet disorders, and hepatic dysfunction. Their use is generally avoided after 32 weeks of gestation.
• Magnesium Sulfate: Contraindicated in patients with myasthenia gravis and severe renal impairment.

Special Considerations

The use of tocolytics demands careful evaluation in specific patient populations due to altered pharmacokinetics, pharmacodynamics, or unique risk-benefit ratios.

Use in Pregnancy and Lactation

All tocolytics are used during pregnancy, and their selection is dictated by gestational age and fetal considerations. As discussed, indomethacin is typically avoided after 32 weeks due to fetal ductal effects. Regarding lactation, most tocolytics are considered compatible with breastfeeding, though data are often limited. Beta-agonists like terbutaline are excreted in breast milk in small amounts but are unlikely to affect the neonate. Nifedipine is excreted in milk, but the relative infant dose is low (<1% of maternal weight-adjusted dose). Indomethacin is also excreted in small quantities. Magnesium sulfate levels in milk are not significantly elevated. For atosiban, breastfeeding is not recommended due to a lack of data.

Renal and Hepatic Impairment

Renal Impairment: Dosage adjustment is critical for drugs primarily excreted renally. Magnesium sulfate requires significant dose reduction and frequent serum monitoring in renal failure due to the high risk of accumulation and toxicity. The dosing of atosiban may also require caution, though specific guidelines are not well-established. NSAIDs like indomethacin are generally contraindicated in significant renal impairment due to the risk of further reducing renal blood flow.

Hepatic Impairment: Agents with extensive hepatic metabolism require caution. The metabolism of nifedipine may be impaired in liver disease, potentially leading to elevated levels and prolonged effects. Beta-agonists and NSAIDs should also be used with caution in severe hepatic dysfunction.

Pediatric and Geriatric Considerations

By definition, tocolytics are used in women of reproductive age, making pediatric and geriatric considerations largely non-applicable. The focus remains on the pregnant patient and the fetus.

Multiple Gestation

Multiple pregnancies are at higher risk for preterm labor and are more susceptible to certain tocolytic complications. The risk of pulmonary edema with beta-agonists and magnesium sulfate is elevated in twin and higher-order pregnancies. Careful fluid management and close monitoring are essential.

Summary/Key Points

• Tocolytic agents are pharmacologically diverse drugs used to suppress uterine contractions, primarily to delay preterm birth and allow for critical interventions like antenatal corticosteroid administration.
• Major classes include beta₂-adrenergic agonists (ritodrine, terbutaline), calcium channel blockers (nifedipine), cyclooxygenase inhibitors (indomethacin), oxytocin receptor antagonists (atosiban), magnesium sulfate, and nitric oxide donors (nitroglycerin).
• Mechanisms of action target key pathways in myometrial contraction: increasing cAMP (beta-agonists), blocking calcium influx (nifedipine), inhibiting prostaglandin synthesis (NSAIDs), antagonizing oxytocin receptors (atosiban), and competing with calcium (magnesium).
• Pharmacokinetics vary widely, influencing the route of administration (IV for atosiban, magnesium, acute beta-agonist therapy; oral for nifedipine, indomethacin) and dosing frequency.
• Nifedipine is often a first-line oral agent due to a favorable balance of efficacy and maternal tolerability. Indomethacin may be used before 32 weeks but is limited by fetal ductus arteriosus effects. Atosiban offers a targeted mechanism with minimal cardiovascular effects.
• Adverse effect profiles are class-specific: cardiovascular (beta-agonists), vasodilatory (nifedipine), fetal ductal/renal (indomethacin), and dose-dependent neuromuscular (magnesium).
• Significant drug interactions exist, particularly between beta-agonists and corticosteroids (increased pulmonary edema risk) and nifedipine with CYP3A4 inhibitors (increased toxicity).
• Contraindications must be respected, including maternal cardiac conditions for beta-agonists, renal disease for magnesium and NSAIDs, and advanced gestation for indomethacin.
• Therapy requires individualized agent selection based on gestational age, maternal comorbidities, and fetal status, with close monitoring for efficacy and adverse effects.

Clinical Pearls

• The primary goal of acute tocolysis is a 48-hour delay in delivery, not the prevention of preterm birth indefinitely.
• Maternal tachycardia and tremor are almost universal with intravenous beta-agonist therapy and often necessitate dose reduction but rarely require discontinuation.
• When using nifedipine, immediate-release capsules are used, but they should be swallowed, not administered sublingually, to avoid rapid hypotension.
• Indomethacin therapy should be accompanied by fetal surveillance, including periodic ultrasound assessments for ductal flow and amniotic fluid volume, especially if used beyond 48 hours.
• Serum magnesium levels, deep tendon reflexes, respiratory rate, and urine output must be monitored frequently during magnesium sulfate infusion to prevent toxicity.
• Tocolytic therapy is only one component of preterm labor management; it should always be combined with antenatal corticosteroids if between 24 and 34 weeks and considered for group B streptococcus prophylaxis.

References

1. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
2. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
3. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
4. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
5. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
6. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
7. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
8. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.